Head-To-Head Review: Sinopharm Group (SHTDF) and Its Rivals

Earnings and Valuation

This table compares Sinopharm Group and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sinopharm Group	N/A	N/A	2.14
Sinopharm Group Competitors	$20.57 billion	$280.23 million	0.97

Sinopharm Group’s competitors have higher revenue and earnings than Sinopharm Group. Sinopharm Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Sinopharm Group and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sinopharm Group	N/A	N/A	N/A
Sinopharm Group Competitors	-5.58%	-137.93%	-0.40%

Insider & Institutional Ownership

16.5% of Sinopharm Group shares are owned by institutional investors. Comparatively, 57.6% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 15.3% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Sinopharm Group pays an annual dividend of $0.26 per share and has a dividend yield of 12.2%. Sinopharm Group pays out 26.1% of its earnings in the form of a dividend. As a group, “Healthcare Providers & Services” companies pay a dividend yield of 1.6% and pay out 25.3% of their earnings in the form of a dividend.

Summary

Sinopharm Group beats its competitors on 5 of the 9 factors compared.

Sinopharm Group Company Profile

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.